Registry-listed formulations

cositecan · mesh:C406143

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

7 source entries across 7 studies. This list may not include all unresolved or historical entries.

  • karenitecinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • karenitecinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Karenitecin (BNP1350)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Karenitecin (BNP1350)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Karenitecin (BNP1350)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • KarenitecinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • KarenitecinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Phase 3
1
13%
Phase 1
2
25%
Phase 2
4
50%
Phase 1/2
1
13%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 1/2Combined phases
1(12.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (25.0%)
Phase 1/21 (12.5%)
Phase 24 (50.0%)
Phase 31 (12.5%)

Trials by Status

completed788%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

NCT00062478
completedphase_2

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

NCT00062491
completedphase_1

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

NCT00097903
completedphase_3

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

NCT00477282
completedphase_2

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00054119
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00062478Phase 2

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Completed
NCT00062491Phase 2

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

Completed
NCT00097903Phase 1

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

Completed
NCT00477282Phase 3

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

Completed
NCT00054119Phase 2

Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed
NCT00010218Phase 2

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

Completed
NCT00358319Phase 1/2

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

Terminated
NCT00014521Phase 1

Karenitecin in Treating Patients With Recurrent Malignant Glioma

Completed

All 8 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
8

External References

ChEMBL
CHEMBL1997373

Names & Codes

Research Codes

BNP-1350